CACTIN

Summary

CACTIN (cactin, spliceosome C complex subunit, HGNC:29938) is a protein-coding gene on chromosome 19p13.3, encoding Splicing factor Cactin (Q8WUQ7). Plays a role in pre-mRNA splicing by facilitating excision of a subset of introns. It is a common-essential gene (DepMap: required in 96.1% of cancer cell lines).

Enables RNA binding activity. Involved in several processes, including cellular response to cytokine stimulus; negative regulation of cytokine production; and negative regulation of signal transduction. Located in cytosol and nuclear speck. Part of catalytic step 2 spliceosome.

Source: NCBI Gene 58509 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 108 total
• Cancer dependency (DepMap): dependent in 96.1% of screened cell lines (common-essential)
• MANE Select transcript: NM_001080543

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29938
Approved symbol	CACTIN
Name	cactin, spliceosome C complex subunit
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	NY-REN-24, fSAPc
Ensembl gene	ENSG00000105298
Ensembl biotype	protein_coding
OMIM	618536
Entrez	58509

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron

ENST00000221899, ENST00000248420, ENST00000429344, ENST00000585942, ENST00000587175, ENST00000588749, ENST00000589321, ENST00000591726, ENST00000591978, ENST00000592721, ENST00000918263

RefSeq mRNA: 2 — MANE Select: NM_001080543 NM_001080543, NM_021231

CCDS: CCDS45920

Canonical transcript exons

ENST00000429344 — 10 exons

Exon	Start	End
ENSE00000664365	3620707	3620802
ENSE00001672817	3610645	3612413
ENSE00003591531	3613464	3613586
ENSE00003620216	3614397	3614589
ENSE00003634395	3613058	3613365
ENSE00003644846	3619080	3619242
ENSE00003645665	3620127	3620272
ENSE00003662668	3618875	3618989
ENSE00003739939	3623688	3624162
ENSE00003845105	3626596	3626790

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 89.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.2302 / max 133.8733, expressed in 1803 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178324	12.8624	1801
178323	0.3678	162

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	89.80	gold quality
granulocyte	CL:0000094	89.01	gold quality
right ovary	UBERON:0002118	87.72	gold quality
left ovary	UBERON:0002119	87.71	gold quality
right hemisphere of cerebellum	UBERON:0014890	86.62	gold quality
olfactory bulb	UBERON:0002264	86.44	silver quality
lower esophagus mucosa	UBERON:0035834	86.29	gold quality
type B pancreatic cell	CL:0000169	86.25	gold quality
left uterine tube	UBERON:0001303	85.94	gold quality
cerebellar hemisphere	UBERON:0002245	85.66	gold quality
cerebellar cortex	UBERON:0002129	85.60	gold quality
lower esophagus muscularis layer	UBERON:0035833	85.58	gold quality
lower esophagus	UBERON:0013473	85.56	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	85.55	gold quality
apex of heart	UBERON:0002098	85.31	gold quality
body of uterus	UBERON:0009853	85.22	gold quality
gastrocnemius	UBERON:0001388	85.15	gold quality
mucosa of transverse colon	UBERON:0004991	85.05	gold quality
popliteal artery	UBERON:0002250	84.90	gold quality
tibial artery	UBERON:0007610	84.89	gold quality
left testis	UBERON:0004533	84.67	gold quality
right testis	UBERON:0004534	84.66	gold quality
muscle layer of sigmoid colon	UBERON:0035805	84.63	gold quality
stromal cell of endometrium	CL:0002255	84.60	gold quality
cerebellum	UBERON:0002037	84.60	gold quality
tibial nerve	UBERON:0001323	84.59	gold quality
skin of leg	UBERON:0001511	84.54	gold quality
aorta	UBERON:0000947	84.48	gold quality
body of stomach	UBERON:0001161	84.42	gold quality
muscle of leg	UBERON:0001383	84.36	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.16

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting CACTIN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-6882-5P	99.35	71.13	1206
HSA-MIR-5190	99.15	67.76	1234
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-4710	98.61	65.96	1048
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-4266	98.53	67.29	1035
HSA-MIR-4717-5P	98.19	67.97	894
HSA-MIR-3155A	98.16	66.09	965
HSA-MIR-3155B	98.16	66.09	965
HSA-MIR-484	98.16	66.92	1074
HSA-MIR-4483	98.09	64.12	1642
HSA-MIR-146B-3P	97.83	65.29	782
HSA-MIR-663B	97.40	62.91	664
HSA-MIR-6859-3P	97.26	64.69	428
HSA-MIR-6849-3P	97.25	64.57	1371

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 96.1% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 3)

• results indicate that PKC-mediated cortactin phosphorylation might be implicated in the maintenance of growth cone (PMID:26033110)
• TRIM39 negatively regulates the NFkappaB signaling pathway possibly via stabilization of cactin. (PMID:26363554)
• cellular complexes comprising cactin, DHX8 and SRRM2 sustain precise chromosome segregation, genome stability and cell proliferation by allowing faithful splicing of specific pre-mRNAs. (PMID:28062851)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cactin	ENSDARG00000059866
mus_musculus	Cactin	ENSMUSG00000034889
rattus_norvegicus	Cactin	ENSRNOG00000039852
drosophila_melanogaster	cactin	FBGN0031114
caenorhabditis_elegans		WBGENE00012230

Paralogs (2): PQBP1 (ENSG00000102103), MARVELD3 (ENSG00000140832)

Protein

Protein identifiers

Splicing factor Cactin — Q8WUQ7 (reviewed: Q8WUQ7)

Alternative names: Renal carcinoma antigen NY-REN-24

All UniProt accessions (5): Q8WUQ7, K7EIU6, K7EMQ0, K7ENY9, K7EQE3

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in pre-mRNA splicing by facilitating excision of a subset of introns. Required for the splicing of CDCA5/Sororin, a regulator of sister chromatid cohesion. Involved in the regulation of innate immune response. Acts as a negative regulator of Toll-like receptor, interferon-regulatory factor (IRF) and canonical NF-kappa-B signaling pathways. Contributes to the regulation of transcriptional activation of NF-kappa-B target genes in response to endogenous pro-inflammatory stimuli.

Subunit / interactions. Interacts (via N-terminal domain) with NFKBIL1; the interaction occurs in a pro-inflammatory-independent manner. Does not interact with RELA NF-kappa-B subunit. Identified in the spliceosome C complex. Interacts with SF3B1. Interacts with SDE2. Interacts with SRRM2. Interacts with DHX8. Interacts with isoform 2 of TRIM39 (via domain B box-type).

Subcellular location. Nucleus. Cytoplasm. Cytosol.

Induction. Up-regulated by TNF/TNFA (at protein level).

Miscellaneous. Antigen recognized by autologous antibody in patients with renal-cell carcinoma. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the CACTIN family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8WUQ7-1	1	yes
Q8WUQ7-2	2

RefSeq proteins (2): NP_001074012, NP_067054 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018816	Cactin_central	Domain
IPR019134	Cactin_C	Domain

Pfam: PF09732, PF10312

UniProt features (19 total): compositionally biased region 6, region of interest 3, modified residue 3, cross-link 2, coiled-coil region 2, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
8C6J	ELECTRON MICROSCOPY	2.8
6QDV	ELECTRON MICROSCOPY	3.3
9FMD	ELECTRON MICROSCOPY	3.3
7W5A	ELECTRON MICROSCOPY	3.6
7W5B	ELECTRON MICROSCOPY	4.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WUQ7-F1	69.52	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 126, 476, 559, 469, 484

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-72163	mRNA Splicing - Major Pathway
R-HSA-72172	mRNA Splicing
R-HSA-72203	Processing of Capped Intron-Containing Pre-mRNA
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 187 (showing top): GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_RESPONSE_TO_TYPE_I_INTERFERON, GOBP_NEGATIVE_REGULATION_OF_INNATE_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_REGULATION_OF_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS

GO Biological Process (19): mRNA splicing, via spliceosome (GO:0000398), negative regulation of protein phosphorylation (GO:0001933), negative regulation of lipopolysaccharide-mediated signaling pathway (GO:0031665), obsolete negative regulation of NF-kappaB transcription factor activity (GO:0032088), negative regulation of interferon-beta production (GO:0032688), negative regulation of interleukin-8 production (GO:0032717), negative regulation of tumor necrosis factor production (GO:0032720), negative regulation of toll-like receptor signaling pathway (GO:0034122), negative regulation of canonical NF-kappaB signal transduction (GO:0043124), innate immune response (GO:0045087), mRNA cis splicing, via spliceosome (GO:0045292), negative regulation of innate immune response (GO:0045824), negative regulation of type I interferon-mediated signaling pathway (GO:0060339), cellular response to lipopolysaccharide (GO:0071222), cellular response to interleukin-1 (GO:0071347), cellular response to tumor necrosis factor (GO:0071356), immune system process (GO:0002376), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), cytoplasm (GO:0005737), cytosol (GO:0005829), nuclear speck (GO:0016607), catalytic step 2 spliceosome (GO:0071013)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
mRNA Splicing	1
Processing of Capped Intron-Containing Pre-mRNA	1
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
negative regulation of response to biotic stimulus	2
negative regulation of signal transduction	2
negative regulation of response to external stimulus	2
cellular response to cytokine stimulus	2
RNA processing	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
regulation of protein phosphorylation	1
protein phosphorylation	1
negative regulation of protein modification process	1
negative regulation of phosphorylation	1
lipopolysaccharide-mediated signaling pathway	1
regulation of lipopolysaccharide-mediated signaling pathway	1
negative regulation of type I interferon production	1
interferon-beta production	1
regulation of interferon-beta production	1
negative regulation of cytokine production	1
interleukin-8 production	1
regulation of interleukin-8 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
negative regulation of tumor necrosis factor superfamily cytokine production	1
toll-like receptor signaling pathway	1
negative regulation of immune system process	1
regulation of toll-like receptor signaling pathway	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
negative regulation of intracellular signal transduction	1
immune response	1
defense response to symbiont	1
mRNA splicing, via spliceosome	1
negative regulation of defense response	1
innate immune response	1
regulation of innate immune response	1
negative regulation of immune response	1
negative regulation of cytokine-mediated signaling pathway	1
negative regulation of innate immune response	1
type I interferon-mediated signaling pathway	1
regulation of type I interferon-mediated signaling pathway	1

Protein interactions and networks

STRING

1240 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CACTIN	TRIM39	Q9HCM9	697
CACTIN	FAM32A	Q9Y421	608
CACTIN	SDE2	Q6IQ49	591
CACTIN	TRIM9	Q9C026	561
CACTIN	TWF2	Q6IBS0	527
CACTIN	TWF1	Q12792	507
CACTIN	PRKRIP1	Q9H875	506
CACTIN	BUD31	P41223	468
CACTIN	CRNKL1	Q9BZJ0	456
CACTIN	SNW1	Q13573	436
CACTIN	TRIM11	Q96F44	427
CACTIN	TAB2	Q9NYJ8	423
CACTIN	SLU7	O95391	413
CACTIN	RNF216	Q9NWF9	397
CACTIN	GID8	Q9NWU2	371

IntAct

92 interactions, top by confidence:

A	B	Type	Score
CSNK2A1	EIF3J	psi-mi:“MI:0914”(association)	0.810
CSNK2B	RPS6KA5	psi-mi:“MI:0914”(association)	0.660
DHX8	AHCYL1	psi-mi:“MI:0914”(association)	0.640
CSNK2B	RPS6KA4	psi-mi:“MI:0914”(association)	0.640
CHCHD10	CLPX	psi-mi:“MI:0914”(association)	0.640
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
SUMO1	CBX4	psi-mi:“MI:0914”(association)	0.600
CLK2	CACTIN	psi-mi:“MI:0915”(physical association)	0.560
JPH4	ZSWIM8	psi-mi:“MI:0914”(association)	0.530
CLEC3A	ZZEF1	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
HSP90AA1	EDRF1	psi-mi:“MI:0914”(association)	0.530
STEEP1	KLHL36	psi-mi:“MI:0914”(association)	0.530
EZH1	EPOP	psi-mi:“MI:0914”(association)	0.530
FGF13	MARK3	psi-mi:“MI:0914”(association)	0.530
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
CACTIN	SPTAN1	psi-mi:“MI:0915”(physical association)	0.400
HMGB2	CACTIN	psi-mi:“MI:0915”(physical association)	0.370
Crnkl1	PLRG1	psi-mi:“MI:0914”(association)	0.350
Isy1	PFDN6	psi-mi:“MI:0914”(association)	0.350
PPP4R3A	COG4	psi-mi:“MI:0914”(association)	0.350
N	RBM47	psi-mi:“MI:0914”(association)	0.350
CSNK2B	OSBPL8	psi-mi:“MI:0914”(association)	0.350
FBL	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (147): CACTIN (Affinity Capture-MS), CACTIN (Affinity Capture-MS), CACTIN (Two-hybrid), CACTIN (Affinity Capture-MS), CACTIN (Proximity Label-MS), CACTIN (Affinity Capture-MS), CACTIN (Affinity Capture-MS), CACTIN (Affinity Capture-MS), CACTIN (Two-hybrid), TRIM39 (Affinity Capture-Western), CACTIN (Reconstituted Complex), CACTIN (Affinity Capture-Western), CACTIN (Proximity Label-MS), CACTIN (Affinity Capture-MS), CACTIN (Affinity Capture-MS)

ESM2 similar proteins: A1A4P4, A1CH36, A2ALW5, A5AAL8, B0BN56, O42911, O70279, P0C2B7, P58468, P83565, Q0CLE8, Q1ECT8, Q290P4, Q2GVC2, Q3SZ86, Q4G0I0, Q4V7Q1, Q5B4U6, Q5BJW9, Q5RFR4, Q5XJW2, Q61733, Q6RUT7, Q753F1, Q7SDU5, Q7SHR9, Q80ZS3, Q86TS9, Q8BGX2, Q8BK72, Q8CHP5, Q8SPE7, Q8TAE8, Q8VD26, Q8WUQ7, Q96AN5, Q96DF8, Q9BRP8, Q9BSF4, Q9BYN8

Diamond homologs: B6KG46, F1Q8W0, F4I2J8, G5EG14, Q8WUQ7, Q9VR99, Q9CS00, O14342

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 127 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	5	24.4×	9e-05
mRNA 3’-end processing	8	20.2×	6e-07
RNA Polymerase II Transcription Termination	6	16.9×	8e-05
mRNA Splicing	10	14.1×	4e-07
Transport of Mature mRNA derived from an Intron-Containing Transcript	7	13.7×	5e-05
rRNA modification in the nucleus and cytosol	5	12.0×	2e-03
Processing of Capped Intron-Containing Pre-mRNA	11	11.6×	4e-07
mRNA Splicing - Major Pathway	15	10.5×	4e-09

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	6	41.4×	2e-06
ribosomal small subunit biogenesis	7	14.4×	9e-05
regulation of alternative mRNA splicing, via spliceosome	5	11.0×	8e-03
mRNA splicing, via spliceosome	13	10.7×	2e-07
RNA processing	5	9.9×	1e-02
RNA splicing	10	8.0×	9e-05
mRNA processing	8	5.7×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

108 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	78
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2223 predictions. Top by Δscore:

Variant	Effect	Δscore
19:3613587:C:CC	acceptor_gain	1.0000
19:3614396:CCGGG:C	donor_gain	1.0000
19:3614588:ACCTG:A	acceptor_loss	1.0000
19:3618869:CGTTA:C	donor_loss	1.0000
19:3618870:GTTAC:G	donor_loss	1.0000
19:3618871:TTAC:T	donor_loss	1.0000
19:3618872:TA:T	donor_loss	1.0000
19:3618873:A:T	donor_loss	1.0000
19:3618874:C:CG	donor_loss	1.0000
19:3618885:G:A	donor_gain	1.0000
19:3618985:TAGAC:T	acceptor_gain	1.0000
19:3618986:AGAC:A	acceptor_gain	1.0000
19:3618987:GAC:G	acceptor_gain	1.0000
19:3618988:AC:A	acceptor_gain	1.0000
19:3618988:ACCT:A	acceptor_loss	1.0000
19:3618989:CC:C	acceptor_gain	1.0000
19:3618989:CCTGG:C	acceptor_loss	1.0000
19:3618990:C:CC	acceptor_gain	1.0000
19:3619075:GGTAC:G	donor_loss	1.0000
19:3619076:GTACC:G	donor_loss	1.0000
19:3619077:TA:T	donor_loss	1.0000
19:3619078:A:AC	donor_gain	1.0000
19:3619078:ACC:A	donor_loss	1.0000
19:3619079:C:CC	donor_gain	1.0000
19:3619079:C:G	donor_loss	1.0000
19:3619238:TGGAA:T	acceptor_gain	1.0000
19:3619239:GGAA:G	acceptor_gain	1.0000
19:3619239:GGAAC:G	acceptor_gain	1.0000
19:3619240:GAA:G	acceptor_gain	1.0000
19:3619240:GAAC:G	acceptor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000027897 (19:3628437 G>T), RS1000055477 (19:3614689 CCTCCT>C), RS1000090360 (19:3619065 G>A,C), RS1000119889 (19:3618891 G>A,C), RS1000177861 (19:3621456 G>A), RS1000228476 (19:3610921 G>A), RS1000258738 (19:3615316 C>T), RS1000467917 (19:3623331 C>A,T), RS1000470398 (19:3619411 T>A,C,G), RS1000482230 (19:3615435 C>T), RS1000556981 (19:3620003 G>A), RS1000597800 (19:3616349 G>A,C,T), RS1000774915 (19:3611498 C>T), RS1000779906 (19:3620529 A>C), RS1000842851 (19:3619594 A>C,G)

Disease associations

OMIM: gene MIM:618536 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001762_131	Obesity-related traits	6.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004626	IGFBP-3 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	decreases sumoylation	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	increases expression	1
perfluorooctanoic acid	increases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Zoledronic Acid	decreases expression	1
Fulvestrant	increases methylation	1
Air Pollutants	increases abundance, increases expression	1
Vehicle Emissions	decreases expression	1
Cisplatin	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Ribonucleotides	affects binding	1
Thiram	increases expression	1
Urethane	increases expression	1
Valproic Acid	increases methylation	1
Okadaic Acid	increases expression	1
Particulate Matter	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.